Phase 2 Trial of Icalcaprant for MDD: Assessing Efficacy and Safety
A Phase 2 trial is evaluating the efficacy and safety of oral Icalcaprant in 195 adults with MDD. Primary outcomes include changes in MADRS scores and adverse events.
Researchers are studying a new drug called Icalcaprant for treating major depression. They will compare its effects to a placebo, which looks like the drug but has no active ingredients.…
Ketamine in Orthopedic Trauma: Potential to Reduce Pain and Opioid Use
This Phase 4 trial investigates ketamine's efficacy in reducing postoperative pain and opioid use in orthopedic trauma patients. Primary outcomes include pain intensity measured by VAS and opioid cons…
This study looks at whether ketamine can help reduce pain and improve mental health in patients after surgery for serious injuries. Researchers want to see if ketamine lowers the need for opioid paink…
Serum Zinc and Iron Levels Reduced in MDD; Copper Levels Elevated
Meta-analysis of 16 studies shows MDD patients have lower serum zinc (SMD = -0.62; 95% CI: -0.78 to -0.46) and iron (SMD = -0.36; 95% CI: -0.52 to -0.20), but higher copper (SMD = +0.42; 95% CI: +0.18…
Researchers looked at the levels of zinc, iron, and copper in people with major depression. They found that those with depression had lower levels of zinc and iron, but higher levels of copper compare…
Sense of Coherence Tied to Health Factors in Long-Term Impaired Work Ability
In a cross-sectional study of 243 patients with long-term sick leave, sense of coherence correlated with health literacy, quality of life, and mental health symptoms (p<0.001), but not sick leave dura…
Researchers looked at patients with long-term work difficulties and found many face serious health challenges. Most reported low quality of life and mental health issues.…